Respective prevalence of high‐risk HPVgenotypes in cervical neoplasia in Senegal. Issue 8 (23rd April 2021)

• Record Type: Journal Article
• Authors: Diop‐Ndiaye, Halimatou; Sastre‐Garau, Xavier; Drame, Aboubacry; Dembele, Birama; Ba, Nafissatou N.; Diop‐Diongue, Oumy; Mbow, Madeleine; Diakhaby, Mba E. B.; Woto‐Gaye, Gisele; Toure Kane, Coumba; Diop, Mamadou
• Is Part Of: Journal of medical virology. Volume 93:Issue 8(2021)
• Page Start: 5110
• Page End: 5117
• Publication Date: 2021-04-23
• Subjects: cervical neoplasia -- high‐risk HPV -- HPV negative cervical cancers; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27020
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Objectives: With the perspective of prophylactic vaccination against high‐risk human papillomavirus (HPV), we analyzed the viral epidemiology of cervical neoplasia in Senegal. Methods: All patients were treated at the Institut Joliot Curie du Cancer in Dakar. HPV genotypes were characterized using a real‐time polymerase chain reaction‐based approach and sequencing. Results: Histologically, there were 224 invasive carcinomas, 17 high‐grade intraepithelial neoplasia (CIN), and five undetermined histologies. Molecular analysis was conclusive in 241 cases. HPV DNA was found in 207/241 (85.9%) cases while 34/241 (14.1%) remained HPV negative. There was one single genotype in 127/207 (61.4%) cases and several in 80/207 (38.6%) corresponding to 308 genotypes identified. Viral genotyping found HPV16 in 175 (56.8%) cases, HPV18 in 45 (14.6%), HPV45 in 40 (13.0%), HPV58 in 35 (11.4%), HPV33 in 6 (2.0%), HPV35 in 3 (1.0%), HPV31 in 2 (0.6%), HPV39 and HPV56 in one (0.3% each). Conclusion: Our analysis showed that 98.4% of the HPV‐positive cases were associated with viral genotypes covered by the 9‐valent HPV vaccine. However, 14.1% of cases remained HPV negative. Therefore, prophylactic vaccination using a 9‐valent vaccine should dramatically reduce the incidence of HPV‐associated neoplasia but the detection and treatment of CIN remain necessary for the optimal prevention of cervical cancer.